Sunday December 8, 2019
Home Lead Story Patients With...

Patients With Hard-To-Treat Depression, A New Drug ‘Special K’ At Rescue

Depression is among the leading causes of disability in the U.S. and is being closely monitored by health authorities amid rising suicides nationwide.

0
//
Depression
A vial of ketamine, which is normally stored in a locked cabinet, is seen in Chicago, July 25, 2018. VOA

A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness.

The nasal spray from Johnson & Johnson is a chemical cousin of ketamine, which has been used for decades as a powerful anesthetic to prepare patients for surgery. In the 1990s, the medication was adopted as a party drug by the underground rave culture due to its ability to produce psychedelic, out-of-body experiences. More recently, some doctors have given ketamine to people with depression without formal FDA approval.

The Food and Drug Administration approved Spravato as a fast-acting treatment for patients who have failed to find relief with at least two antidepressants. Up to 7.4 million American adults suffer from so-called treatment-resistant depression, which heightens the risk of suicide, hospitalization and other serious harm, according to the FDA.

The drug will cost between $590 and $885 depending on the dosage and before various insurance discounts and rebates.

There have been no major pharmaceutical innovations for depression since the launch of Prozac and related antidepressants in the late 1980s. Those drugs target the feel-good brain chemical serotonin, and can take weeks or months to kick in.

Ketamine and J&J’s version work differently than those drugs, targeting a chemical called glutamate that is thought to restore brain connections that help relieve depression.

When the drug works, its effect is almost immediate. That speed “is a huge thing because depressed patients are very disabled and suffer enormously,” said Dr. John Mann, a psychiatrist and researcher at Columbia University. If the drug doesn’t work, physicians can quickly switch to other options, he noted.

The FDA approved Spravato, known chemically as esketamine, based on study results that showed patients taking the drug experienced a bigger improvement in their depression levels than patients taking a sham treatment, when measured with a psychiatric questionnaire.

The drug is designed to be lower-dose and easier to use than ketamine, which is normally given as an intravenous infusion.

Robin Prothro, 60, began taking antidepressants more than 20 years ago. But she says none of the five medications she tried relieved the depression that has stymied her personal and professional life.

Since enrolling in a Spravato trial two years ago, Prothro says her depression has lifted and she’s returned to hobbies she abandoned years ago, like gardening.

She takes the drug every two weeks at her psychiatrist’s office while reclining in a comfortable chair.

“You can feel it coming on, it’s a strong drug,” she said, describing colors and shapes that drift before her eyes. “I just let the drug work. I close my eyes and my mind is amazingly quiet.”

Psychedelics reconsidered

The ketamine-like drug is the first of several psychoactive substances making their way through the U.S. regulatory process as physicians search further afield for new therapies. Researchers are conducting late-stage trials of psilocybin, the active ingredient in magic mushrooms, and MDMA, a euphoria-inducing club drug, as potential treatments for depression and post-traumatic stress disorder.

Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago, July 25, 2018.
Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago, July 25, 2018. VOA

“Substantially different agents are only rarely appearing from pharmaceutical companies or other laboratories,” said Dr. Paul Summergrad, a psychiatrist at Tufts University. “That’s prompting people to investigate other compounds.”

Unlike ketamine, psilocybin and MDMA have no legal medical use. Classified in the same category as heroin and LSD, they are tightly restricted by the federal government. But the FDA’s approval of esketamine could smooth their path.

Burden of depression

Depression is among the leading causes of disability in the U.S. and is being closely monitored by health authorities amid rising suicides nationwide. In 2017, the U.S. suicide rate rose to 14 deaths per 100,000 people, the highest rate in at least 50 years, according to federal records.

Government officials haven’t suggested an explanation for the trend, though academic researchers point to the nation’s widening income gap, financial struggles and divisive politics.

J&J’s drug will be subject to a number of restrictions due to its abuse potential, side effects and lingering safety questions.

The drug will only be given by accredited specialists who must monitor patients for at least two hours after administration, due to its trippy, disorienting effects. Additionally, all patients will be tracked in a registry to monitor long-term safety and effectiveness.

The immediate impact of ketamine is thought to last just four to seven days and there’s no consensus yet on how long patients can benefit from ongoing treatment.

sad
Depression is among the leading causes of disability in the U.S. and is being closely monitored by health authorities amid rising suicides nationwide. Pixabay

Still, there are few other options for patients who fail to respond to antidepressants. The most effective treatment in such cases, electroshock therapy, requires patients to be fully sedated and can cause persistent memory loss.

Wall Street has high expectations for J&J’s medication, with analysts predicting more than $600 million in annual sales by 2022. But J&J will face competition in the marketplace.

A decades-old drug, ketamine is already used off-label to treat depression by some doctors. At least 150 clinics around the U.S. provide treatment with various forms of the drug, which is available as a low-cost generic. Patients often pay hundreds or thousands of dollars for intravenous infusions of the drug over several weeks or months. Such therapies are generally not covered by insurance because they haven’t been approved as safe and effective by FDA regulators.

Also Read: Hospital in Jordan Gives War Victims New Hope, Develops 3D-printed Prosthetics for War Victims

Some doctors plan to offer both ketamine and the new J&J drug.

Dr. Steve Levine says having FDA-approved standards for dosing and administering the new drug should raise standards in the field and drive out some of the bad actors who are not qualified to treat depression.

“This is going to bring in some standards, regulation and it’s going to make it safer and more accessible to patients,” said Levine, who serves as vice president of the American Society of Ketamine Physicians, a group representing doctors, nurses and others using ketamine for treating depression or other non-approved uses. (VOA)

Next Story

Depression in Parents Responsible for Brain Differences of Kids

Brain differences detected in kids with depressed parents

0
Brain structure
Researchers detect brain differences in children with depressive parents. Lifetime Stock

Researchers have found structural differences in the brains of children at high risk for depression due to parental depressive history.

Depression is a common and debilitating mental health condition that typically arises during adolescence. While the causes of depression are complex, having a parent with depression is one of the biggest known risk factors.

Studies have consistently shown that adolescent children of parents with depression are two to three times more likely to develop depression than those with no parental history of depression.

“The findings highlight a potential risk factor that may lead to the development of depressive disorders during a peak period of onset, said study author Randy P. Auerbach, Associate Professor at Columbia University in the US.

“However, in our prior research, smaller putamen volumes also has been linked to anhedonia–a reduced ability to experience pleasure–which is implicated in depression, substance use, psychosis, and suicidal behaviours,” Auerbach said.

Depression brain
Having a parent with depression is one of the biggest known risk factors for the brain of the child. Lifetime Stock

“Thus, it may be that smaller putamen volume is a transdiagnostic risk factor that may confer vulnerability to broad-based mental disorders,” Auerbach added.

For the study, published in the Journal of the American Academy of Child & Adolescent Psychiatry, the researchers analysed brain images from over 7,000 children in the United States participating in the Adolescent Brain Cognitive development (ABCD) study, led by the National Institutes of Health (NIH).

According to the study, about one-third of the children were in the high-risk group because they had a parent with depression.

Also Read- Intermittent Fasting Benefits Those at Risk for Diabetes: Study

The research found that in the high-risk children, the right putamen–a brain structure linked to reward, motivation, and the experience of pleasure–was smaller than in children with no parental history of depression.

“Understanding differences in the brains of children with familial risk factors for depression may help to improve early identification of those at greatest risk for developing depression themselves, and lead to improved diagnosis and treatment,” said study researcher David Pagliaccio. (IANS)